Cannara Biotech (LOVE) Q1 2025 earnings summary

Executive summary

• Achieved Q1 2025 net income of $2.3M, up from $2.1M year-over-year, with 15 consecutive quarters of positive EBITDA and strong operating margins.

• Net revenue reached $25.1M–$24.0M, with gross cannabis revenues of $34.9M, driven by premium product demand and three flagship brands.

• Maintained strong cash position ($10.2M–$10.3M), working capital of $36.7M, and total assets of $161.0M.

• Vertically integrated operations in Quebec provide pricing and quality advantages, supported by a strong management team.

• Plans to activate two new grow zones and launch over 20 new products in 2025 to expand market leadership.

Financial highlights

• Q1 2025 gross cannabis revenues: $34.9M; net revenue: $25.1M–$24.0M; gross margin: 39%; net income: $2.3M.

• Gross profit before fair value adjustments: $9.8M; operating income: $4.2M; adjusted EBITDA: $6.0M.

• Operating cash flow: $5.8M; free cash flow: $4.6M; cash on hand: $10.2M–$10.3M.

• Working capital: $36.7M; inventory: $36.2M at quarter-end.

• Basic and diluted EPS: $0.03, up from $0.02 year-over-year.

Outlook and guidance

• Plans to open two new grow zones, increasing capacity by 6,000kg/year, and launch over 20 new products in 2025.

• Focus on scaling production, expanding market share, and driving sustainable revenue growth.

• Management expects existing cash, forecasted cash flows, and undrawn credit facilities to fund operations for at least the next twelve months.

• Canadian legal cannabis market projected to reach US$6.58B by 2029.